Pioneering a novel checkpoint inhibitor
What is CD24?
CD24 is a cell-surface protein that is an important checkpoint for tumor immune response. CD24 is overexpressed in approximately 70% of human cancers, making it a promising checkpoint to target.1 However, targeting CD24 on cancer-specific cells remains a challenge because it is also expressed in normal tissues.
Our CD24 approach
Our cancer-specific antibody targets a neo-CD24 epitope that is exposed only on cancer cells.
Our platform broadly targets cancers with CD24 mutations across solid and liquid tumors. Our multi faceted approach includes a range of treatment modalities to provide the right tool to fight cancer.
ONC-783
By simultaneously engaging two targets, ONC-783 redirects T cells to recognize and eliminate tumor cells that express neoCD24.
ONC-783 shows broad reactivity to hepatocellular carcinoma, breast cancer, ovarian cancer, cervical cancer, neuroblastoma, prostate cancer, lung cancer, and many types of malignant brain tumors.
